

- S1. Lassegue,B., Sorescu,D., Szocs,K., Yin,Q., Akers,M., Zhang,Y., Grant,S.L., Lambeth,J.D., and Griending,K.K. 2001. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. *Circ.Res.* 88:888-894.
- S2. Houston,M., Estevez,A., Chumley,P., Aslan,M., Marklund,S., Parks,D.A., and Freeman,B.A. 1999. Binding of xanthine oxidase to vascular endothelium - Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. *Journal of Biological Chemistry* 274:4985-4994.
- S3. Wink,D.A., Miranda,K.M., Espey,M.G., Pluta,R.M., Hewett,S.J., Colton,C., Vitek,M., Feelisch,M., and Grisham,M.B. 2001. Mechanisms of the antioxidant effects of nitric oxide. *Antioxid.Redox.Signal.* 3:203-213.
- S4. Rubbo,H., Radi,R., Trujillo,M., Telleri,R., Kalyanaraman,B., Barnes,S., Kirk,M., and Freeman,B.A. 1994. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. *J.Biol.Chem.* 269:26066-26075.
- S5. Ferdinandy,P., Danial,H., Ambrus,I., Rothery,R.A., and Schulz,R. 2000. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. *Circ.Res.* 87:241-247.
- S6. Yasmin,W., Strynadka,K.D., and Schulz,R. 1997. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. *Cardiovasc.Res.* 33:422-432.
- S7. Romeo,A.A., Capobianco,J.A., and English,A.M. 2003. Superoxide dismutase targets NO from GSNO to Cys beta 93 of oxyhemoglobin in concentrated but not dilute solutions of the protein. *Journal of the American Chemical Society* 125:14370-14378.
- S8. Stamler,J.S. and Hausladen,A. 1998. Oxidative modifications in nitrosative stress. *Nature Structural Biology* 5:247-249.
- S9. Simon,D.I., Mullins,M.E., Jia,L., Gaston,B., Singel,D.J., and Stamler,J.S. 1996. Polynitrosylated proteins: characterization, bioactivity, and functional consequences. *Proc.Natl.Acad.Sci.USA* 93:4736-4741.
- S10. Hare,J.M. 2004. Spatial confinement of isoforms of cardiac nitric-

oxide synthase: unravelling the complexities of nitric oxide's cardiobiology. *Lancet* 363:1338-1339.

S11. Viner,R.I., Ferrington,D.A., Williams,T.D., Bigelow,D.J., and Schoneich,C. 1999. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca²⁺-ATPase in skeletal muscle. *Biochemical Journal* 340:657-669.

S12. Hare,J.M. 2004. Nitroso-Redox balance in the cardiovascular system. *N Eng J Med* 351:2112-2114.

S13. Campbell,D.L., Stamler,J.S., and Strauss,H.C. 1996. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. *J.Gen.Physiol.* 108:277-293.

S14. Pinsky,D., Patton,S., Mesaros,S., Brovkovich,V., Kubaszewski,E., Grunfeld,S., and Malinski,T. 1997. Mechanical transduction of nitric oxide synthesis in the beating heart. *Circ.Res.* 81:372-379.

S15. Hare,J.M., Lofthouse,R.A., Juang,G.J., Colman,L., Ricker,K.M., Kim,B., Senzaki,H., Cao,S., Tunin,R.S., and Kass,D.A. 2000. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. *Circ.Res.* 86:1085-1092.

S16. Vatner,D.E., Sato,N., Kiuchi,K., Shannon,R.P., and Vatner,S.F. 1994. Decrease in myocardial ryanodine receptors and altered excitation-contraction coupling early in the development of heart failure. *Circulation* 90:1423-1430.

S17. Shannon,T.R., Ginsburg,K.S., and Bers,D.M. 2002. Quantitative assessment of the SR Ca²⁺ leak-load relationship. *Circ Res* 91:594-600.

S18. Kawakami,M. and Okabe,E. 1998. Superoxide anion radical-triggered Ca²⁺ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca²⁺ channel. *Mol Pharmacol* 53:497-503.

S19. Marks,A.R., Reiken,S., and Marx,S.O. 2002. Progression of Heart Failure: Is Protein Kinase A Hyperphosphorylation of the Ryanodine Receptor a Contributing Factor? *Circulation* 105:272-275.

S20. Marx,S.O., Reiken,S., Hisamatsu,Y., Jayaraman,T., Burkhoff,D., Rosemblyt,N., and Marks,A.R. 2000. PKA phosphorylation dissociates FKBP12.6 from

the calcium release channel (ryanodine receptor): defective regulation in failing hearts. *Cell* 101:365-376.

S21. Prestle,J., Janssen,P.M., Janssen,A.P., Zeitz,O., Lehnart,S.E., Bruce,L., Smith,G.L., and Hasenfuss,G. 2001. Overexpression of FK506-Binding Protein FKBP12.6 in Cardiomyocytes Reduces Ryanodine Receptor-Mediated Ca(2+) Leak From the Sarcoplasmic Reticulum and Increases Contractility. *Circ Res* 88:188-194.

S22. Yano,M., Ono,K., Ohkusa,T., Suetsugu,M., Kohno,M., Hisaoka,T., Kobayashi,S., Hisamatsu,Y., Yamamoto,T., Noguchi,N. *et al.* 2000. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. *Circulation* 102:2131-2136.

S23. de Jong,J.W., Schoemaker,R.G., de Jonge,R., Bernocchi,P., Keijzer,E., Harrison,R., Sharma,H.S., and Ceconi,C. 2000. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. *J Mol Cell Cardiol* 32:2083-2089.

S24. Perez,N.G., Gao,W.D., and Marban,E. 1998. Novel myofilament Ca²⁺-sensitizing property of xanthine oxidase inhibitors. *Circulation Research* 83:423-430.

S25. Ekelund,U.E.G., Harrison,R.W., Shokek,O., Thakkar,R.N., Tunin,R.S., Senzaki,H., Kass,D.A., Marbán,E., and Hare,J.M. 1999. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. *Circ Res* 85:437-445.

S26. Stull,L.B., Leppo,M.K., Szweda L, Gao WD, and Marbán,E. 2004. Chronic Treatment With Allopurinol Boosts Survival and Cardiac Contractility in Murine Postischemic Cardiomyopathy. *Circ Res.* 95:1005-1011.

S27. Engberding,N., Spiekermann,S., Schaefer,A., Heineke,A., Wiencke,A., Muller,M., Fuchs,M., Hilfiker-Kleiner,D., Hornig,B., Drexler,H. *et al.* 2004. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction - A new action for an old drug? *Circulation* 110:2175-2179.

S28. Cherednichenko,G., Zima,A.V., Feng,W., Schaefer,S., Blatter,L.A., and Pessah,I.N. 2004. NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. *Circulation Research* 94:478-486.

S29. Berkowitz,D.E., White,R., Li,D.C., Minhas,K.M., Cernetich,A.,

Kim,S., Burke,S., Shoukas,A.A., Nyhan,D., Champion,H.C. *et al.* 2003. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. *Circulation* 108:2000-2006.

S30. Boger,R.H., Bode-Boger,S.M., Szuba,A., Tsao,P.S., Chan,J.R., Tangphao,O., Blaschke,T.F., and Cooke,J.P. 1998. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction - Its role in hypercholesterolemia. *Circulation* 98:1842-1847.

S31. Tyurin,V.A., Liu,S.X., Tyurina,Y.Y., Sussman,N.B., Hubel,C.A., Roberts,J.M., Taylor,R., and Kagan,V.E. 2001. Elevated levels of S-nitrosoalbumin in preeclampsia plasma. *Circulation Research* 88:1210-1215.

S32. Massy,Z.A., Fumeron,C., Borderie,D., Tuppin,P., Nguyen-Khoa,T., Benoit,M.O., Jacquot,C., Buisson,C., Drueke,T.B., Ekindjian,O.G. *et al.* 2004. Increased plasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: A prospective study. *Journal of the American Society of Nephrology* 15:470-476.

S33. Gandley RE, Tyurin,V.A., Huang W, Arroyo A, Daftary A, Harger G, Jiang J, Pitt B, Taylor RN, Hubel CA *et al.* 2005. S-Nitrosoalbumin-Mediated Relaxation Is Enhanced by Ascorbate and Copper: Effects in Pregnancy and Preeclampsia Plasma. *Hypertension* 45:21-27.

S34. Gonzalez-Alonso,J., Richardson,R.S., and Saltin,B. 2001. Exercising skeletal muscle blood flow in humans responds to reduction in arterial oxyhaemoglobin, but not to altered free oxygen. *Journal of Physiology-London* 530:331-341.

S35. Roach,R.C., Koskolou,M.D., Calbet,J.A.L., and Saltin,B. 1999. Arterial O₂ content and tension in regulation of cardiac output and leg blood flow during exercise in humans. *American Journal of Physiology-Heart and Circulatory Physiology* 276:H438-H445.

S36. Pawloski,J.R., Hess,D.T., and Stamler,J.S. 2005. Impaired vasodilation by red blood cells in sickle cell disease. *Proc Natl Acad Sci U S A* in press.

S37. James,P.E., Land D, Tufnell-Barrett,T., Milsom,A., and Frenneaux,M. 2004. Vasorelaxation by red blood cells and impairment in diabetes:

reduced nitric oxide and oxygen delivery by glycated hemoglobin. *Circ Res* 94:976-983.

S38. Wilson,J.R., Mancini,D.M., and Dunkman,W.B. 1993. Exertional Fatigue Due to Skeletal-Muscle Dysfunction in Patients with Heart-Failure. *Circulation* 87:470-475.

S39. Pawloski,J.R., Hess,D.T., and Stamler,J.S. 2001. Export by red blood cells of nitric oxide bioactivity. *Nature* 409:622-626.

S40. Dimmeler,S., Haendeler,J., Nehls,M., and Zeiher,A.M. 1997. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. *Journal of Experimental Medicine* 185:601-607.

S41. Mannick,J.B., Hausladen,A., Liu,L., Hess,D.T., Zeng,M., Miao,Q.X., Kane,L.S., Gow,A.J., and Stamler,J.S. 1999. Fas-induced caspase denitrosylation. *Science* 284:651-654.

S42. Park,H.S., Yu,J.W., Cho,J.H., Kim,M.S., Huh,S.H., Ryoo,K., and Choi,E.J. 2004. Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism. *Journal of Biological Chemistry* 279:7584-7590.

S43. Park,H.S., Huh,S.H., Kim,M.S., Lee,S.H., and Choi,E.J. 2000. Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. *Proceedings of the National Academy of Sciences of the United States of America* 97:14382-14387.

S44. Nikitovic,D., Holmgren,A., and Spyrou,G. 1998. Inhibition of AP-1 DNA binding by nitric oxide involving conserved cysteine residues in Jun and Fos. *Biochemical and Biophysical Research Communications* 242:109-112.

S45. Haendeler,J., Hoffmann,J., Tischler,V., Berk,B.C., Zeiher,A.M., and Dimmeler,S. 2002. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. *Nature Cell Biology* 4:743-749.

S46. Reynaert,N.L., Ckless,K., Korn,S.H., Vos,N., Guala,A.S., Wouters,E.F.M., van der Vliet,A., and Janssen-Heininger,Y.M.W. 2004. Nitric oxide represses inhibitory kB kinase through S-nitrosylation. *Proceedings of the National Academy of Sciences of the United States of America* 101:8945-8950.

S47. Kim,Y.M., Bombeck,C.A., and Billiar,T.R. 1999. Nitric oxide as a

bifunctional regulator of apoptosis. *Circ.Res.* 84:253-256.

S48. Mannick,J.B., Schonhoff,C., Papeta,N., Ghafourifar,P., Szibor,M., Fang,K., and Gaston,B. 2001. S-Nitrosylation of mitochondrial caspases. *J Cell Biol.* 154:1111-1116.

S49. Li,J.M., Gall,N.P., Grieve,D.J., Chen,M.Y., and Shah,A.M. 2002. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. *Hypertension* 40:477-484.

S50. Calderone,A., Thaik,C.M., Takahashi,N., Chang,D.L.F., and Colucci,W.S. 1998. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. *J Clin Invest* 101:812-818.

S51. Wittstein,I.S., Kass,D.A., Maughan,W.L., Pak,P.H., Fetis,B., and Hare,J.M. 2001. Cardiac nitric oxide production due to angiotensin converting-enzyme inhibition decreases β -adrenergic myocardial contractility in patients with dilated cardiomyopathy. *J.Am.Coll.Cardiol.* 38:429-435.

S52. Haendeler,J., Hoffmann,J., Zeiher,A.M., and Dimmeler,S. 2004. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells - A novel vasculoprotective function of statins. *Circulation* 110:856-861.

S53. Laufs,U., La Fata,V., Plutzky,J., and Liao,J.K. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation* 97:1129-1135.

S54. Carson,P., Ziesche,S., Johnson,G., and Cohn,J.N. 1999. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. *J Card Fail* 5:178-187.

S55. Cohn,J.N., Johnson,G., Ziesche,S., Cobb,F., Francis,G., Tristani,F., Smith,R., Dunkman,W.B., Loeb,H., Wong,M.L. *et al.* 1991. A Comparison of Enalapril with Hydralazine Isosorbide Dinitrate in the Treatment of Chronic Congestive-Heart-Failure. *New England Journal of Medicine* 325:303-310.

S56. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinandy K, Taylor M, Adams K, Sabolinski M, Worcel M *et al.* 2004. The African-

American heart failure trial: Efficacy of combined isosorbide-dinitrate and hydralazine in advanced heart failure. *N Engl J Med* 351:2057.

S57. Leiro,J.M., Alvarez,E., Arranz,J.A., Cano,E., and Orallo,F. 2004. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. *International Immunopharmacology* 4:163-177.

S58. Munzel,T., Kurz,S., Rajagopalan,S., Thoenes,M., Berrington,W.R., Thompson,J.A., Freeman,B.A., and Harrison,D.G. 1996. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. *J.Clin.Invest* 98:1465-1470.

S59. Sydow,K., Daiber,A., Oelze,M., Chen,Z.Q., August,M., Wendt,M., Ullrich,V., Mulsch,A., Schulz,E., Keaney,J.F. *et al.* 2004. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. *Journal of Clinical Investigation* 113:482-489.

S60. Massey,V., Komai,H., Palmer,G., and Elion,G.B. 1970. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo [3,4-d]pyrimidines. *J.Biol.Chem.* 245:2837-2844.

S61. Elion,G.B. 1989. The Purine Path to Chemotherapy. *Science* 244:41-47.

S62. Spiekermann,S., Landmesser,U., Dikalov,S., Bredt,M., Gamez,G., Tatge,H., Reepschlager,N., Hornig,B., Drexler,H., and Harrison,D.G. 2003. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease - Relation to endothelium-dependent vasodilation. *Circulation* 107:1383-1389.

S63. Freudenberger,R.S., Schwarz,R.P., Brown,J., Moore,A., Mann,D., Givertz,M.M., Colucci,W.S., and Hare,J.M. 2004. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. *Expert Opinion on Investigational Drugs* 13:1509-1516.

S64. Han,X., Kubota,I., Feron,O., Opel,D.J., Arstall,M.A., Zhao,Y., Huang,P., Fishman,M.C., Michel,T., and Kelly,R.A. 1998. Muscarinic cholinergic

regulation of cardiac myocyte I_{Ca-L} is absent in mice with targeted disruption of endothelial nitric oxide synthase. *Proc Natl Acad Sci U.S.A.* 95:6510-6515.

S65. Clementi, E., Brown, G.C., Feelisch, M., and Moncada, S. 1998. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. *Proc Natl Acad Sci U.S.A.* 95:7631-7636.

S66. Kanai, A.J., Pearce, L.L., Clemens, P.R., Birder, L.A., VanBibber, M.M., Choi, S.Y., de Groat, W.C., and Peterson, J. 2001. Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. *Proc. Natl. Acad. Sci. U.S.A.* 98:14126-14131.

S67. Kobzik, L., Stringer, B., Balligand, J.L., Reid, M.B., and Stamler, J.S. 1995. Endothelial Type Nitric-Oxide Synthase in Skeletal-Muscle Fibers - Mitochondrial Relationships. *Biochemical and Biophysical Research Communications* 211:375-381.